{"id":14211,"date":"2011-10-22T10:30:00","date_gmt":"2011-10-22T08:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/antitrust-ue-nel-mirino-johnson-johnson-e-novartis\/"},"modified":"2011-10-22T10:30:00","modified_gmt":"2011-10-22T08:30:00","slug":"antitrust-ue-nel-mirino-johnson-johnson-e-novartis","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/antitrust-ue-nel-mirino-johnson-johnson-e-novartis\/","title":{"rendered":"EU antitrust, Johnson &amp; Johnson and Novartis in the sights"},"content":{"rendered":"<p style=\"line-height: normal; margin: 0cm 0cm 3.75pt\" class=\"MsoNormal\"><span style=\"font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT\">From <strong>Simone Ricci&nbsp;&nbsp;&nbsp; <\/strong><\/span><\/p>\n<p style=\"line-height: normal; margin: 0cm 0cm 10pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto\" class=\"MsoNormal\"><span style=\"font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT\">There <strong><em>European Commission<\/em><\/strong> announced yesterday that it had launched an investigation against two giants such as <a href=\"http:\/\/www.google.it\/url?sa=t&amp;rct=j&amp;q=johnson%20%26%20johnson&amp;source=web&amp;cd=1&amp;sqi=2&amp;ved=0CDAQFjAA&amp;url=http%3A%2F%2Fwww.jnj.com%2F&amp;ei=rFKiTszODI3LsgattJmaAw&amp;usg=AFQjCNEGLDp997k22egjFGfwtGGgJLcD0w\" target=\"_blank\" rel=\"noopener\"><span style=\"color: windowtext; text-decoration: none; text-underline: none\">Johnson &amp; Johnson<\/span><\/a> And <a href=\"http:\/\/www.google.it\/url?sa=t&amp;rct=j&amp;q=novartis%20finanzalive&amp;source=web&amp;cd=2&amp;ved=0CCYQFjAB&amp;url=http%3A%2F%2Fwww.finanzalive.com%2Fflash-news%2Fnovartis-quota-maggioranza-alcon-inc%2F&amp;ei=dlKiTqH-Mc7tsgbossCkAw&amp;usg=AFQjCNFGFB-Ycc3mwCdKHUwWnbvspHUJLw\" target=\"_blank\" rel=\"noopener\"><span style=\"color: windowtext; text-decoration: none; text-underline: none\">Novartis<\/span><\/a>: L&#039;<strong>Community antitrust<\/strong> it is therefore ready to ascertain a new flaw, also because there is a strong suspicion that the multinationals in question may have restricted market access to generic competitors in the Netherlands. Brussels, as is known, also holds these powers to protect competition and the market and its objective in this case will be to ascertain whether the pharmaceutical company of New Brunswick and that of Basel have actually collaborated to exclude other potential companies from the related sector at <strong>generic versions of <em>Fentanyl<\/em><\/strong>, one of the most powerful synthetic medicines.<\/p>\n<p> The latter was in fact introduced fifty years ago as an anesthetic; currently, however, after the 2005 patent it is intended for cancer patients. In detail, the third quarter of 2011 was characterized by <strong>sales amounted to 155 million <em>dollars<\/em><\/strong> for another Johnson &amp; Johnson drug, namely Duragesic; the drop compared to the previous three months was really substantial, almost sixteen percentage points (-15.8%), a decline that many justified with the very strong competition. Among other things, there are other pharmaceutical versions developed by Novartis itself and by the American <strong><em>Milan<\/em><\/strong>. As already mentioned, the investigation concerns the Swiss company, but it has not yet wanted to provide other details in this regard, unlike J&amp;J, which is <strong>collaborating quite effectively<\/strong>.<\/p>\n<p><\/span><\/p>\n<p style=\"line-height: normal; margin: 0cm 0cm 10pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto\" class=\"MsoNormal\"><em style=\"mso-bidi-font-style: normal\"><span style=\"font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 10pt; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT\">October 22, 2011 \u2013 <img loading=\"lazy\" decoding=\"async\" style=\"width: 128px; height: 30px\" id=\"rg_hi\" class=\"rg_hi\" alt=\"\" width=\"165\" height=\"38\" data-height=\"38\" data-width=\"165\" src=\"http:\/\/t2.gstatic.com\/images?q=tbn:ANd9GcR7MlsydxfcVtYqdMgvWFTv-3BB8mbUseJ0HKkT66fJhJvXkM5k_w\" \/><\/span><\/em><\/p>\n<p>&nbsp;<\/p>\n<p style=\"margin: 0cm 0cm 10pt\" class=\"MsoNormal\"><span","protected":false},"excerpt":{"rendered":"<p>Di Simone Ricci&nbsp;&nbsp;&nbsp; La Commissione Europea ha comunicato nel corso della giornata di ieri di aver avviato un&rsquo;istruttoria contro due colossi quali Johnson &amp; Johnson e Novartis: l&rsquo;Antitrust comunitaria &egrave; dunque pronta ad accertare una nuova magagna, anche perch&eacute; c&rsquo;&egrave; il forte sospetto che le multinazionali in questione possano aver ristretto l&rsquo;accesso del mercato ai &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-14211","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/14211","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=14211"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/14211\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=14211"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=14211"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=14211"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}